Peptidomimetic Probes and Molecular Modeling Suggest That Alzheimer's γ-Secretase Is an Intramembrane-Cleaving Aspartyl Protease
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The amyloid beta-protein (Abeta), implicated in the pathogenesis of Alzheimer's disease (AD), is a proteolytic metabolite generated by the sequential action of beta- and gamma-secretases on the amyloid precursor protein (APP). The two main forms of Abeta are 40- and 42-amino acid C-terminal variants, Abeta40 and Abeta42. We recently described a difluoro ketone peptidomimetic (1) that blocks Abeta production at the gamma-secretase level [Wolfe, M. S., et al. (1998) J. Med. Chem. 41, 6-9]. Although designed to inhibit Abeta42 production, 1 also effectively blocked Abeta40 formation. Various amino acid changes in 1 still resulted in inhibition of Abeta40 and Abeta42 production, suggesting relatively loose sequence specificity by gamma-secretase. The alcohol counterparts of selected difluoro ketones also lowered Abeta levels, indicating that the ketone carbonyl is not essential for activity and suggesting that these compounds inhibit an aspartyl protease. Selected compounds inhibited the aspartyl protease cathepsin D but not the cysteine protease calpain, corroborating previous suggestions that gamma-secretase is an aspartyl protease with some properties similar to those of cathepsin D. Also, since the gamma-secretase cleavage sites on APP are within the transmembrane region, we consider the hypothesis that this region binds to gamma-secretase as an alpha-helix and discuss the implications of this model for the mechanism of certain forms of hereditary AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [16]
Citations
Cites
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Cell Biology of the Amyloid beta-Protein Precursor and the Mechanism of Alzheimer's Disease
Selkoe, D. J. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.002105 · Cited by 747
Self-citationRawson, R. B., Zelenski, N. G., Nijhawan, D., Ye, J., Sakai, J., Hasan, M. T., Chang, T. Y., Brown, M. S., & Goldstein, J. L. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80006-4 · Cited by 429
Intracellular Generation and Accumulation of Amyloid β-Peptide Terminating at Amino Acid 42
Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., & Haass, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16085 · Cited by 303
Leonhard, K., Herrmann, J. M., Stuart, R. A., Mannhaupt, G., Neupert, W., & Langer, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00796.x · Cited by 286
A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity
Wolfe, M. S., Citron, M., Diehl, T. S., Xia, W., Donkor, I. O., & Selkoe, D. J. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970621b · Cited by 215
Self-citationInhibition and catalytic mechanism of HIV-1 aspartic protease
Silva, A. M., Cachau, R. E., Sham, H. L., & Erickson, J. W. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0026 · Cited by 178
Klafki, H.-W., Abramowski, D., Swoboda, R., Paganetti, P. A., & Staufenbiel, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28655 · Cited by 159
Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D
Ladror, U. S., Snyder, S. W., Wang, G. T., Holzman, T. F., & Krafft, G. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32325-6 · Cited by 129
Research works printed but not linked: 36
- Tomita T., 1998, Neuroreport 9, 911−3
- Ross S. L., 1998, J. Biol. Chem., 273
- Selkoe D. J., 1997, Science 275, 630−1
- Hardy, 2095, J. (1997)
- Roher A. E., 1993, Proc. Natl. Acad. Sci. U.S.A. 90, 10836−40
- Jarrett J. T., 1993, Biochemistry 32, 4693−7
- Selkoe D. J., 1998, Abstract 8.3.
- Fehrentz J.-A., 1983, Synthesis, 676−8
- Xia W., 1997, J. Biol. Chem., 272
- Citron M., 1996, Proc. Natl. Acad. Sci. U.S.A. 93, 13170−5
- Johnson-Wood K., 1997, Proc. Natl. Acad. Sci. U.S.A. 94, 1550−5
- Seubert P., 1992, Nature 359, 325−7
- Buroker-Kilgore M., 1993, Anal. Biochem. 208, 387−92
- Weidemann A., 1989, Cell 57, 115−26
- Cook D. G., 1997, 3, 1021−3
- Hartmann T., 1997, 3, 1016−20
- Hardy J., 1997, Trends Neurosci. 20, 154−9
- Sakai J., 1996, Cell 85, 1037−46
- Schroeter E. H., 1998, Nature 393, 382−6
- Higaki J., 1995, Neuron 14, 651−9
- Wang K. K., 1990, Trends Pharmacol. Sci. 11, 139−42
- Mellgren R. L., 1997, Biochem. Biophys. Res. Commun. 236, 555−8
- Evin G., 1995, Biochemistry 34, 14185−92
- Doherty A. M., 1992, J. Med. Chem., 35, 14
- Maruyama K., 1996, Biochem. Biophys. Res. Commun. 227, 730−5
- Lichtenthaler S. F., 1997, Biochemistry 36, 15396−403
- Yamazaki T., 1997, Biochemistry 36, 8377−83
- Haass C., 1992, Nature 357, 500−3
- Parris K. D., 1992, Biochemistry 31, 8125−41
- James M. N., 1992, Biochemistry 31, 3872−86
- Veerapandian B., 1992, Protein Sci. 1, 322−8
- Takahashi L. H., 1989, J. Am. Chem. Soc., 111
- Duncan E. A., 1998, J. Biol. Chem., 273
- Walz T., 1997, Nature 387, 624−7
- Cheng A., 1997, Nature 387, 627−30
- Wolfe M. S., 1999, Nature (in press)
Cited by
Items 101–200 of 293
Berezovska, O., Jack, C., Deng, A., Gastineau, N., Rebeck, G. W., & Hyman, B. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008268200 · Cited by 82
Chang, Y., Tesco, G., Jeong, W. J., Lindsley, L., Eckman, E. A., Eckman, C. B., Tanzi, R. E., & Guénette, S. Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309561200 · Cited by 80
Tian, G., Ghanekar, S. V., Aharony, D., Shenvi, A. B., Jacobs, R. T., Liu, X. F., & Greenberg, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300905200 · Cited by 83
ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by γ-secretase
Chalaris, A., Gewiese, J., Paliga, K., Fleig, L., Schneede, A., Krieger, K., Rose‐John, S., & Scheller, J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.12.001 · Cited by 92
Miralles, F., Lamotte, L., Couton, D., & Joshi, R. L. (2005) · The International Journal of Developmental Biology · doi:10.1387/ijdb.052080fm · Cited by 81
“…Notch pathway blocks FGF10 effects on growth and cell differentiation To further demonstrate that the effects of FGF10 on the pancreatic rudiments were mediated by the activation of the Notch pathway, we cultured FGF10 treated rudiments with compound 1, a γ-secretase inhibitor (Wolfe et al., 1999).”
BackgroundIndependent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase
Czirr, E., Cottrell, B. A., Leuchtenberger, S., Kukar, T., Ladd, T. B., Esselmann, H., Paul, S., Schubenel, R., Torpey, J. W., Pietrzik, C. U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802912200 · Cited by 72
Pastorcic, M., & Das, H. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005411200 · Cited by 58
Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice
Rodrigo, J., Fernández‐Vizarra, P., Castro‐Blanco, S., Bentura, M. L., Nieto, M., Gómez‐Isla, T., Martínez‐Murillo, R., Martínez, A., Serrano, J., & Fernández, A. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.030 · Cited by 77
Hoshino, N., Katayama, N., Shibasaki, T., Ohishi, K., Nishioka, J., Masuya, M., Miyahara, Y., Hayashida, M., Shimomura, D., Kato, T., et al. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1204746 · Cited by 71
“The -secretase inhibitor II has been reported to inhibit the Notch signal by blocking Notch cleavage [ 32 , 33].”
BackgroundHeilig, E. A., Gutti, U., Tai, T., Shen, J., & Kelleher, R. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0954-13.2013 · Cited by 69
“Further support for this interpretation comes from the widely reported yet enigmatic ability of transition-state analog inhibitors of -secretase to stimulate A 42 production while inhibiting A 40 production (Wolfe et al., 1999; Li et al., 2000; Zhang et al., 2001).”
BackgroundTamboli, I. Y., Prager, K., Thal, D. R., Thelen, K. M., Dewachter, I., Pietrzik, C. U., St. George-Hyslop, P., Sisodia, S. S., De Strooper, B., Heneka, M. T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2635-08.2008 · Cited by 68
“Consis- tent with previous studies (De Strooper et al., 1998; Wolfe et al., 1999a; Wolfe et al., 1999b), we observed a strong accumulation of APP CTFs in PS-deficient cells and after inhibition of -secretase activity by DAPT (supplemental Fig.”
Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure
Vorobyeva, A. G., & Saunders, A. J. (2018) · Cilia · doi:10.1186/s13630-018-0059-y · Cited by 67
In search of γ-secretase: Presenilin at the cutting edge
Selkoe, D. J., & Wolfe, M. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.5690 · Cited by 66
Self-citationγ-Secretase Inhibition and Modulation for Alzheimers Disease
Wolfe, M. S. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954767 · Cited by 77
Self-citationSelkoe, D. J. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)00054-9 · Cited by 70
Self-citationA novel mechanism for the regulation of amyloid precursor protein metabolism
Chen, Q., Kimura, H., & Schubert, D. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110151 · Cited by 63
“-Secretase inhibitor II, which has no effect, is thought to be an aspartyl protease inhibitor, which selectively inhibits the -secretase cleavage of APP and Notch-1 proteolysis (Wolfe et al., 1998; 1999; De Strooper et al., 1999; Berezovska et al., 2000; Esler et al., 2000).”
BackgroundInfluentialA Role for Notch Signaling in Human Corneal Epithelial Cell Differentiation and Proliferation
Ma, A., Boulton, M. E., Zhao, B., Connon, C. J., Cai, J., & Albon, J. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-1373 · Cited by 65
“Concentrations of -secretase inhibitor and Jagged1 were chosen because of their previously reported respective inhibitory and stimulatory effects on the Notch pathway.(9,21) Control”
BackgroundWang, J., Brunkan, A. L., Hecimovic, S., Walker, E., & Goate, A. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.008 · Cited by 62
Marambaud, P., & Robakis, N. K. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00086.x · Cited by 64
“…and two aspartyl residues within transmembrane domain VI and VII of presenilins are required for the g-secretase cleavage of APP (Kimberly et al. 2000; Steiner et al. 1999; Wolfe et al. 1999b) and other substrates such as Notch-1 (Steiner et al. 1999) or N-cadherin (Marambaud et al. 2003).”
BackgroundThe Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression
Burton, C. R., Meredith, J. E., Barten, D. M., Goldstein, M. E., Krause, C., Kieras, C. J., Sisk, L. M., Iben, L. G., Polson, C. T., Thompson, M. W., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804175200 · Cited by 63
Craft, D., Wein, L. M., & Selkoe, D. J. (2002) · Bulletin of Mathematical Biology · doi:10.1006/bulm.2002.0304 · Cited by 71
Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease
Beher, D., & Graham, S. L. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1385 · Cited by 66
“Studies with transition-state analogue inhibitors have indicated that γ-secretase has the characteristics of an aspartyl-type protease [71,72].”
Backgroundγ-Secretase: a complex target for Alzheimer's disease
Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 66
Pharmacotherapeutic targets in Alzheimer's disease
Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., & Adlard, P. A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00595.x · Cited by 57
Cutting Proteins within Lipid Bilayers: Rhomboid Structure and Mechanism
Lemberg, M. K., & Freeman, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.12.003 · Cited by 66
Computational Modeling of Substrate Specificity and Catalysis of the β-Secretase (BACE1) Enzyme
Barman, A., Schürer, S. C., & Prabhakar, R. S. (2011) · Biochemistry · doi:10.1021/bi200081h · Cited by 60
The Metalloprotease Meprin β Is an Alternative β-Secretase of APP
Becker-Pauly, C., & Pietrzik, C. U. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00159 · Cited by 52
“The γ-secretase is an aspartyl protease complex (Wolfe et al., 1999), which unlike αand β-secretases, acts within the membrane and cleaves APP at multiple sites (Zhao et al., 2004), releasing either, Aβ and intracellular C-terminal domain fragments (ICDs) or p3 and ICDs (Figure 1).”
BackgroundIntramembrane Proteolysis in Regulated Protein Trafficking
Lemberg, M. K. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01219.x · Cited by 61
“Within the endocytic compartments and the trans-Golgi network, highest rate of APP shedding by β-secretase is observed (94).”
BackgroundInfluentialTherapeutic approaches to Alzheimer’s disease
Thorsett, E. D., & Latimer, L. H. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00102-2 · Cited by 66
The same γ‐secretase accounts for the multiple intramembrane cleavages of APP
Zhao, G., Tan, J., Mao, G., Cui, M., & Xu, X. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04302.x · Cited by 52
Xia, W., Ostaszewski, B. L., Kimberly, W. T., Rahmati, T., Moore, C. L., Wolfe, M. S., & Selkoe, D. J. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0322 · Cited by 51
“Two fully conserved aspartates within the 6th and 7th transmembrane (TM) domains of all presenilins have been shown to be critical for Aß generation (Kimberly et al., 2000; Steiner et al., 1999; Wolfe et al., 1999a).”
BackgroundSelf-citationPresenilins and the intramembrane proteolysis of proteins: facts and fiction
Strooper, B. D., & Annaert, W. G. (2001) · Nature Cell Biology · doi:10.1038/ncb1001-e221 · Cited by 57
Pathogenic mechanisms in Alzheimer's disease
Pastorino, L., & Lu, K. P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.078 · Cited by 60
Unraveling the complexity of γ-secretase
Wolfe, M. S. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.005 · Cited by 55
Self-citationNotch Inhibition Promotes Human Embryonic Stem Cell-Derived Cardiac Mesoderm Differentiation
Jang, J., Ku, S., Kim, J. E., Choi, K., Kim, Y. Y., Kim, H. S., Oh, S. K., Lee, E. J., Cho, H., Song, Y. H., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1053 · Cited by 49
Structure, mechanism and inhibition of γ-secretase and presenilin-like proteases
Wolfe, M. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.086 · Cited by 56
“These findings led to the identification of two conserved transmembrane aspartates in the multi-pass presenilins that are crucial for g-secretase cleavage of APP (Figure 1A), evidence that presenilins are aspartyl proteases (Steiner et al., 1999; Wolfe et al., 1999c).”
Self-citationPARL Protease: A Glimpse at Intramembrane Proteolysis in the Inner Mitochondrial Membrane
Lysyk, L., Brassard, R., Touret, N., & Lemieux, M. J. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.04.006 · Cited by 49
Substrate recognition and processing by γ-secretase
Wolfe, M. S. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.07.004 · Cited by 53
“These clues led to the discovery of the two conserved TMD aspartates as essential for γ-secretase activity and the recognition that presenilin is an unusual protease with a membrane-embedded active site (Wolfe et al., 1999b).”
BackgroundSelf-citationSubstrate Recognition and Binding by RseP, an Escherichia coli Intramembrane Protease
Koide, K., Ito, K., & Akiyama, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709984200 · Cited by 46
Nakaya, Y., Yamane, T., Shiraishi, H., Wang, H., Matsubara, E., Sato, T., Dolios, G., Wang, R., Strooper, B. D., Shoji, M., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501130200 · Cited by 45
Toward the structure of presenilin/γ-secretase and presenilin homologs
Wolfe, M. S. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.015 · Cited by 51
Self-citationPresenilin and γ‐secretase: structure meets function
Wolfe, M. S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00245.x · Cited by 49
“…PS1 or PS2 resulted in a dominant negative effect, lowering Ab production and raising levels of g-secretase substrates C83 and C99 (i.e. effects similar to knocking out PS1) (Leimer et al. 1999; Steiner et al. 1999a; Steiner et al. 1999c; Wolfe et al. 1999b; Kimberly et al. 2000; Yu et al. 2000).”
BackgroundSelf-citationNeuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
Castellani, R. J., Zhu, X., Lee, H., Moreira, P. I., Perry, G. L., & Smith, M. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.473 · Cited by 45
Campbell, W. A., Reed, M. L. O., Strahle, J., Wolfe, M. S., & Xia, W. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01799.x · Cited by 35
Self-citationOctave, J.-N., Essalmani, R., Tasiaux, B., Menager, J., Czech, C., & Mercken, L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.3.1525 · Cited by 42
Probing pockets S2–S4′ of the γ-secretase active site with (hydroxyethyl)urea peptidomimetics
Esler, W. P., Das, C., & Wolfe, M. S. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.01.077 · Cited by 42
Self-citationMann, D. M. A., Takeuchi, A., Sato, S., Cairns, N. J., Lantos, P. L., Rossor, M. N., Haltia, M., Kalimo, H., & Iwatsubo, T. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2001.00316.x · Cited by 42
van den Heuvel, C., Donkin, J. J., Finnie, J. W., Blumbergs, P. C., Kuchel, T. R., Koszyca, B., Manavis, J., Jones, N. R., Reilly, P. L., & Vink, R. (2004) · Journal of Neurotrauma · doi:10.1089/0897715042441783 · Cited by 41
γ-Secretase Inhibitors as Molecular Probes of Presenilin Function
Wolfe, M. S. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:199 · Cited by 48
Self-citationThe genetic association between Cathepsin D and Alzheimer's disease
Crawford, F., Freeman, M. J., Schinka, J. A., Abdullah, L. I., Richards, D., Sevush, S., Duara, R., & MULLAN, M. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01260-x · Cited by 43
Spotlight on BACE: The secretases as targets for treatment in Alzheimer disease
Dingwall, C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14402 · Cited by 38
Aspartic Proteases Involved in Alzheimer's Disease
Schmidt, B. (2003) · ChemBioChem · doi:10.1002/cbic.200200532 · Cited by 46
Singh, R. R. P., Barman, A., & Prabhakar, R. S. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp811154w · Cited by 40
Cathepsin D polymorphism not associated with Alzheimer's disease in Japanese
Matsui, T., Morikawa, Y.-I., Tojo, M., Okamura, N., Maruyama, M., Hirai, H., Chiba, H., Matsushita, S., Higuchi, S., Arai, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.110 · Cited by 36
Physiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis
Golde, T. E., & Eckman, C. B. (2003) · Science's STKE · doi:10.1126/stke.2003.172.re4 · Cited by 36
Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease
Mariani, E., Seripa, D., Ingegni, T., Nocentini, G., Mangialasche, F., Ercolani, S., Cherubini, A., Metastasio, A., Pilotto, A., Senin, U., et al. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.043 · Cited by 35
The secretases of Alzheimer's disease
Wolfe, M. S. (2003) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)54011-x · Cited by 35
Self-citationThe Role of Proteolysis in Alzheimer’s Disease
Hooper, N. M., Trew, A. J., Parkin, E. T., & Turner, A. J. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46826-3_39 · Cited by 35
Nowotny, P., Gorski, S. M., Han, S. W., Philips, K., Ray, W. J., Nowotny, V., Jones, C. J., Clark, R. F., Cagan, R. L., & Goate, A. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0805 · Cited by 37
γ-Secretase: characterization and implication for Alzheimer disease therapy
Xu, M., Lai, M., Huang, Q., DiMuzio‐Mower, J., Castro, J. L., Harrison, T., Nadin, A. J., Neduvelil, J. G., Shearman, M. S., Shafer, J. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00126-4 · Cited by 37
Presenilin endoproteolysis is an intramolecular cleavage
Brunkan, A. L., Martínez, M., Walker, E. S., & Goate, A. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.12.012 · Cited by 42
Siman, R., & Salidas, S. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.08.028 · Cited by 36
Secretases as therapeutic targets for the treatment of Alzheimer's disease
Dominguez, D. I., Strooper, B. D., & Annaert, W. G. (2001) · Amyloid · doi:10.3109/13506120109007356 · Cited by 44
Genes involved in Alzheimer's disease, a survey of possible candidates
Serretti, A., Artioli, P., Quartesan, R., & Ronchi, D. D. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7410 · Cited by 35
“In addition, it was hypothesized that gamma secretase is an aspartyl protease [70], and mutation of two aspartate residues in the transmembrane domain of PS1 was reported to inhibit gamma secretase activity [64].”
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 32
Esposito, L., Gan, L., Yu, G., Essrich, C., & Mucke, L. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02816.x · Cited by 31
Fraering, P. C. (2007) · Current Genomics · doi:10.2174/138920207783769521 · Cited by 30
“The first pharmacological evidence supporting an aspartyl protease mechanism for -secretase came with the finding that peptide analogues specifically designed based on the Ala713-Thr714 APP cleavage site leading to A 42 (substrate-based difluoro ketones that mimic an intermediate in aspartyl-protease catalysis) inhibi…”
BackgroundThe Cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease
Riemenschneider, M., Blennow, K., Wagenpfeil, S., Andreasen, N., Prince, J. A., Laws, S. M., Förstl, H., & Kurz, A. (2006) · Human Mutation · doi:10.1002/humu.20326 · Cited by 30
“In addition to these mooted b-secretase properties, CtsD has been suggested to exert a g-secretase like activity [Sadik et al., 1999; Wolfe et al., 1999] and additionally cleaves APP within the Ab sequence, close to the a-secretase site [Hamazaki, 1996].”
BackgroundsiRNA against presenilin 1 (PS1) down regulates amyloid β42 production in IMR-32 cells
Kandimalla, R. J. L., Wani, W. Y., Binukumar, B. K., & Gill, K. D. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-2 · Cited by 31
“Third, the types of compounds that could inhibit g -secretase contained moieties typically found in aspartyl protease inhibitors [7].”
BackgroundLoss of nicastrin elicits an apoptotic phenotype in mouse embryos
Nguyen, V., Hawkins, C. E., Bergeron, C., Supala, A., Huang, J., Westaway, D. A., George‐Hyslop, P. S., & Rozmahel, R. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.122 · Cited by 29
Zhang, J., Ye, W., Wang, R., Wolfe, M. S., Greenberg, B., & Selkoe, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105375200 · Cited by 30
Self-citationA High-Throughput Screen to Identify Inhibitors of Amyloid β-Protein Precursor Processing
Bakshi, P., Liao, Y.-F., Gao, J., Ni, J., Stein, R. L., Yeh, L.-A., & Wolfe, M. S. (2005) · SLAS DISCOVERY · doi:10.1177/1087057104270068 · Cited by 28
Self-citationPresenilin‐1 and intracellular calcium stores regulate neuronal glutamate uptake
Yang, Y., Kinney, G. A., Spain, W. J., Breitner, J. C. S., & Cook, D. G. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02279.x · Cited by 28
Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease
Wolfe, M. S. (2021) · Molecules · doi:10.3390/molecules26020388 · Cited by 28
Self-citationBrunkan, A. L., Martinez, M., Wang, J., Walker, E. S., Beher, D., Shearman, M. S., & Goate, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03278.x · Cited by 33
Discovery of Cellular Roles of Intramembrane Proteases
Beard, H. A., Barniol‐Xicota, M., Yang, J., & Verhelst, S. H. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00404 · Cited by 26
Synthesis of gallic acid based naphthophenone fatty acid amides as cathepsin D inhibitors
Srivastava, V., Saxena, H. O., Shanker, K., Kumar, J. K., Luqman, S., Gupta, M. M., Khanuja, S. P. S., & Negi, A. S. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.06.010 · Cited by 25
Presenilin mutations associated with fronto‐temporal dementia
Hutton, M. L. (2004) · Annals of Neurology · doi:10.1002/ana.20103 · Cited by 28
Liao, Y.-F., Wang, B., Hsu, W., Lee, H., Liao, C.-Y., Wu, S.-Y., Cheng, H.-T., & Hu, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024299 · Cited by 25
γ-Secretase: Substrates and Inhibitors
Rochette, M. J., & Murphy, M. P. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:1:081 · Cited by 29
“aspartyl protease inhibitor pepstatin (93) and peptidomimetic compounds designed to model the transition state of the substrate during cleavage (95).”
BackgroundPresenilins, β-amyloid precursor protein and the molecular basis of Alzheimer's disease
Selkoe, D. J. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00016-5 · Cited by 31
Self-citationEskandari, S., Sajadimajd, S., Alaei, L., Soheilikhah, Z., Derakhshankhah, H., & Bahrami, G. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00381-7 · Cited by 26
The Amyloid Forming Peptides Islet Amyloid Polypeptide and Amyloid β Interact at the Molecular Level
Wang, Y., & Westermark, G. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011153 · Cited by 24
Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors
Kegel, K. B., Sapp, E., Alexander, J. S., Reeves, P., Bleckmann, D., Sobin, L., Masso, N., Valencia, A., Jeong, H., Krainc, D., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-58 · Cited by 26
Facchinetti, F., Fasolato, C., DELGIUDICE, E., Burgo, A., Furegato, S., Fusco, M., Basso, E., Seraglia, R., D'Arrigo, A. M., & Leon, A.-S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.006 · Cited by 26
Gamma secretase inhibitors: a patent review (2013 - 2015)
Gu, K., Li, Q., Lin, H., Zhu, J., Mo, J., He, S., Lü, X., Jiang, X., & Sun, H. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1313231 · Cited by 23
“the serine or cysteine, and the difluoroketone peptidomimetic can inhibit the aspartyl protease [43].”
BackgroundStructure and modeling in the design of β‐ and γ‐secretase inhibitors
Holloway, M. K., Hunt, P. A., & McGaughey, G. B. (2009) · Drug Development Research · doi:10.1002/ddr.20291 · Cited by 26
“…amino acids led to significantly reduced levels of Ab amyloid and one direction for the design of new inhibitors has centered on typical aspartyl protease inhibitor features such as the HEA [Liao et al., 2007] or tetrahedral intermediate mimetics such as fluoroketones [Wolfe et al., 1999a].”
BackgroundResultContinuing strategies for inhibiting alzheimer’s γ-secretase
Wolfe, M. S., Esler, W. P., & Das, C. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0015-5 · Cited by 25
“We previously reported substrate-based difluoro ketone and difluoro alcohol peptidomimetics as transition-state analogue inhibitors of -secretase, and these inhibitors helped characterize the protease as an aspartyl protease with loose sequence specificity (Wolfe et al., 1999b; Moore et al., 2000).”
BackgroundResultSelf-citationPresenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer’s Disease
Wolfe, M. S. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00830 · Cited by 21
Self-citationLaudon, H., Winblad, B. G., & Näslund, J. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.037 · Cited by 20
Glycobiology in the field of aging research—introduction to glycogerontology
Kobata, A. (2003) · Biochimie · doi:10.1016/s0300-9084(03)00003-8 · Cited by 19
Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors
Thompson, L. A., Liauw, A. Y., Ramanjulu, M. M., Kasireddy-Polam, P., Mercer, S. E., Maduskuie, T. P., Glicksman, M. A., Roach, A., Meredith, J. E., Liu, R., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.055 · Cited by 19
Tan, J., Mao, G., Cui, M., Kang, S., Lamb, B. T., Wong, B., Sy, M., & Xu, X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05643.x · Cited by 18
Nuclear Signaling: A Common Function of Presenilin Substrates?
Steiner, H., & Haass, C. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:193 · Cited by 18
Structural and Chemical Biology of Presenilin Complexes
Johnson, D. S., Li, Y., Pettersson, M., & George‐Hyslop, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024067 · Cited by 21
“2) (De Strooper et al. 1999; Nishimura et al. 1999; Wolfe et al. 1999b; Francis et al. 2002; Yu et al. 2000; Chen et al. 2006).”
BackgroundInfluentialEmbedded in the Membrane: How Lipids Confer Activity and Specificity to Intramembrane Proteases
Paschkowsky, S., Oestereich, F., & Munter, L. M. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-0008-5 · Cited by 21
Yücel, S. S., & Lemberg, M. K. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.05.014 · Cited by 17
APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease
Wolfe, M. S. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00179-0 · Cited by 24
Self-citationSecretases as targets for drug design in Alzheimer’s disease
Hendriksen, J. V. R. B., Nottet, H. S. L. M., & Smits, H. A. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00937.x · Cited by 17
Moore, C. L., Diehl, T. S., Selkoe, D. J., & Wolfe, M. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06922.x · Cited by 21
Self-citation
Metadata
- Authors
- Wolfe, M. S., Xia, W., Moore, C. L., Leatherwood, D. D., Ostaszewski, B., Rahmati, T., Donkor, I. O., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Wolfe, Michael S.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-03-26
- Volume
- 38
- Issue
- 15
- Pages
- 4720-4727
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2004305803
- Cited by
- 289
- References
- 12
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 2 · 2017: 8 · 2016: 7 · 2015: 5 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ns037537-02)
- National Institute on Aging (AG 12749, R01AG012749)
- National Heart, Lung, and Blood Institute (HL 3536)
- National Institute of Neurological Disorders and Stroke (NS37537)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- gamma-secretase, Alzheimer's disease, amyloid-beta, aspartic protease, intramembrane cleavage, amyloid precursor protein, cathepsin D, calpain, transmembrane helices, enzyme inhibition
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Humans, Hydrolysis, Ketones, Models, Molecular, Molecular Sequence Data, Endopeptidases, Protease Inhibitors, Protein Binding, Molecular Probes, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Molecular Mimicry, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.